BBIO241220P25000
- 0.28
- -0.17-37.78%
BridgeBio Pharma Newsroom
Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Receives Buy Rating Following Attruby's FDA Approval and Strategic Milestones
Trending Stocks Today | Ambarella Shoots up 24.58% Post-Market
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby (Acoramidis)
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $55
Top Gap Ups and Downs on Monday: SMCI, ZM, GFI and More
Express News | Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $48
12 Health Care Stocks Moving In Monday's Pre-Market Session
BridgeBio Pharma Up Over 16%, on Pace for Largest Percent Increase Since July 2023 -- Data Talk
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY (Acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Sector Update: Health Care
Unusual Options Activity: VFC, MTCH and Others Attract Market Bets, VFC V/OI Ratio Reaches 333.3
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
BridgeBio Shares Surge 25% on FDA Approval of Attruby
Express News | BridgeBio Pharma Inc : UBS Raises Target Price to $54 From $47
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday